About / Partnering / Out-Licensing


Amarin launched Vascepa® using its own sales force in the United States in 2013. To maximize the availability of Vascepa® to patients on a worldwide basis, Amarin has embarked on a strategy to partner the product with companies that have the demonstrated capabilities and commitment to successfully commercialize Vascepa® in their respective territories of the world.

Below are initial examples of partnerships that support our corporate global strategy:

China, Hong Kong, Taiwan
Licensed to Eddingpharm

(click for press release)

Canada
Licensed to HLS Therapeutics

HLS Therapeutics Inc.
(click for press release)

Middle East and North Africa
Distribution with Biologix

(click for press release)

Amarin is seeking leading partners on a worldwide basis to help introduce Vascepa® in their respective markets. Ideal partners would have the following characteristics: well established regional experience and coverage, robust commercial infrastructure, strong track record of successful development and registration of in-licensed products, as well as a therapeutic area fit (cardiovascular, diabetes, obesity, etc.)

For partnering inquiries, please contact our business development team to discuss the Vascepa® opportunity and available Ex-U.S. rights.

Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe